BEST Critical Limb Ischemia (vCLI) Registry
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,009
- 试验地点
- 1
- 主要终点
- Percentage of participants with major adverse limb events (MALE) as measured by patient reports (verified by medical records)
研究概览
简要总结
For subjects with critical limb ischemia, identify patient, physician/hospital, and geographic factors associated with variations in treatment strategies; compare treatments and outcomes, including quality of life, cost and cost effectiveness, at 6, 12 months.
详细描述
The study will be a prospective multicenter registry evaluating the real world therapeutic strategies, clinical outcomes, and costs associated with patients presenting with critical limb ischemia.
Population: Patients over age 18 presenting with critical limb ischemia After initial enrollment at 40 study sites throughout the US. participants will complete follow-up 6 months and 12 months via call center telephone calls.
The study plan calls for enrollment of approximately 1,200 participants throughout the US that will then have 12 month followup that includes collection of medications, hospitalizations for collection of events.Additionally, the BEST-CLI trial will be gathering quality of life data and cost data using similar instruments, thus providing an opportunity for comparison between cost and quality of life analyses in a clinical trial versus in a real-world registry and collection of Quality of Life using validated instruments: EQ-5D, VASQOL, SF-12.and bill review to determine economic impact of disease.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female
- •age 18 years or older
- •Infrainguinal peripheral artery disease (occlusive disease of the arteries below the inguinal ligament)
- •Critical limb ischemia, defined as arterial insufficiency with gangrene, non-healing ischemic ulcer, or rest pain consistent with Rutherford categories 4-6
- •Documented consideration for enrollment in the BEST-CLI Trial with documented failure to meet inclusion / exclusion criteria. Phase ll After BEST CLI official enrollment ends, this inclusion criteria will be removed.
- •Willingness to comply with vCLI protocol, attend follow-up appointments, complete all study assessments, and provide written informed consent.
排除标准
- •Presence of a popliteal aneurysm (> 2 cm) in the index limb
- •Life expectancy of less than 2 years due to reasons other than peripheral artery disease
- •Active vasculitis, Buerger's disease, or acute limb-threatening ischemia
- •Current chemotherapy or radiation therapy
- •Pregnancy or lactation
- •Administration of an investigational drug for peripheral artery disease within 30 days of randomization
- •Participation in a clinical trial (except observational studies) within the previous 30 days
- •Prior enrollment or randomization into the BEST-CLI trial
结局指标
主要结局
Percentage of participants with major adverse limb events (MALE) as measured by patient reports (verified by medical records)
时间窗: 12 months
Number of participants in the registry with major limb events as reported by participants and confirmed by medical records
次要结局
- Number of participants that died within 30 days of index procedure(30 days)
- Number of participants with amputation free survival as measured by patient report/verified by medical record review(12 months)
- Number of participants that did not have secondary interventions in index leg as measured by patient report/verified by medical record review(12 months)
- Quality of life as measure by the validated QOL tool (EuroQol) that will be administered throughout the study(12 month)
- Number of interventions per limb as measured by patient report/verified by medical record review(12 months)
- Number of participants that did not have limb revascularization failure as measured by patient report/verified by medical record review(12 months)
- Number of participants who did not have a myocardial infarction as measured by patient report/verified by medical record review(12 months)
- Number of participants who did not have a stroke while in the registry as measured by patient report/verified by medical record review(12 months)
- Number of participants that did not have a periprocedural (30 day) major adverse cardiac events as measured by patient report/verified by medical record review(6 months)
- Quality of life as measure by the validated QOL tool called the EuroQol that will be administered throughout the study(6 month)
- Quality of life as measured by the the SF-12 instrument that will be administered throughout the study(12 months)